The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Quantifying mutant MYD88 expression to track disease burden in WM
Zachary Hunter, PhD, Dana-Farber Cancer Institute, Boston, MA, presents a study utilizing allele-specific polymerase chain reaction (PCR) assays to quantify mutant MYD88 expression on CD19-selected tissue throughout the development of Waldenström’s macroglobulinemia (WM). The research demonstrates that this approach to tracking disease burden is a better predictor of progression-free survival (PFS) than standard techniques that measure serum IgM changes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
